tetano
Editor, Senior Moderator
Cureus
. 2023 Mar 18;15(3):e36325.
doi: 10.7759/cureus.36325. eCollection 2023 Mar.
Pooled Prevalence of Long COVID-19 Symptoms at 12 Months and Above Follow-Up Period: A Systematic Review and Meta-Analysis
Shiv K Mudgal[SUP] 1 [/SUP], Rakhi Gaur[SUP] 1 [/SUP], Satyaveer Rulaniya[SUP] 2 [/SUP], Latha T[SUP] 3 [/SUP], Rajat Agarwal[SUP] 4 [/SUP], Subodh Kumar[SUP] 5 [/SUP], Saurabh Varshney[SUP] 6 [/SUP], Suresh Sharma[SUP] 2 [/SUP], Sudip Bhattacharya[SUP] 7 [/SUP], Vasantha Kalyani[SUP] 1 [/SUP]
Affiliations
Abstract
Current data suggests that coronavirus disease 2019 (COVID-19) survivors experience long-lasting problems. It is not yet understood how long these symptoms last. The goal of this study was to compile all the data that was currently available to evaluate COVID-19's long-term effects at 12 months and above. We looked for studies published by December 15, 2022, in PubMed and Embase that discussed follow-up findings for COVID-19 survivors who had been alive for at least a year. A random-effect model was carried out to determine the combined prevalence of different long-COVID symptoms. The Joanna Briggs Institute tool was used to assess the risk of bias for the included studies, and the I2 statistics were used to evaluate the heterogeneity. After reviewing 3,209 studies, 46 were deemed admissible, with an aggregate COVID-19 population of 17976. At 12 months and above, 57% of patients reported a minimum of one symptom, and the five most prevalent symptoms were: dyspnea on exertion (34%, 95% CI 0.2; 0.94); difficulty in concentration (32%, 95% CI 0.16; 0.52); fatigue (31%, 95% CI 0.22; 0.40); frailty (31%, 95% CI 0.06; 0.78); and arthromyalgia (28%, 95% CI 0.09; 0.6). The findings of the present study showed that at 12 months and beyond, a sizable fraction of COVID-19 survivors still have lasting symptoms that impair several body systems. Long-COVID patients require an urgent understanding of pathophysiological processes and the development of tailored treatments.
Keywords: a systematic review; long term covid-19; meta-analysis; prevalence; symptoms.
. 2023 Mar 18;15(3):e36325.
doi: 10.7759/cureus.36325. eCollection 2023 Mar.
Pooled Prevalence of Long COVID-19 Symptoms at 12 Months and Above Follow-Up Period: A Systematic Review and Meta-Analysis
Shiv K Mudgal[SUP] 1 [/SUP], Rakhi Gaur[SUP] 1 [/SUP], Satyaveer Rulaniya[SUP] 2 [/SUP], Latha T[SUP] 3 [/SUP], Rajat Agarwal[SUP] 4 [/SUP], Subodh Kumar[SUP] 5 [/SUP], Saurabh Varshney[SUP] 6 [/SUP], Suresh Sharma[SUP] 2 [/SUP], Sudip Bhattacharya[SUP] 7 [/SUP], Vasantha Kalyani[SUP] 1 [/SUP]
Affiliations
- PMID: 37077615
- PMCID: PMC10108372
- DOI: 10.7759/cureus.36325
Abstract
Current data suggests that coronavirus disease 2019 (COVID-19) survivors experience long-lasting problems. It is not yet understood how long these symptoms last. The goal of this study was to compile all the data that was currently available to evaluate COVID-19's long-term effects at 12 months and above. We looked for studies published by December 15, 2022, in PubMed and Embase that discussed follow-up findings for COVID-19 survivors who had been alive for at least a year. A random-effect model was carried out to determine the combined prevalence of different long-COVID symptoms. The Joanna Briggs Institute tool was used to assess the risk of bias for the included studies, and the I2 statistics were used to evaluate the heterogeneity. After reviewing 3,209 studies, 46 were deemed admissible, with an aggregate COVID-19 population of 17976. At 12 months and above, 57% of patients reported a minimum of one symptom, and the five most prevalent symptoms were: dyspnea on exertion (34%, 95% CI 0.2; 0.94); difficulty in concentration (32%, 95% CI 0.16; 0.52); fatigue (31%, 95% CI 0.22; 0.40); frailty (31%, 95% CI 0.06; 0.78); and arthromyalgia (28%, 95% CI 0.09; 0.6). The findings of the present study showed that at 12 months and beyond, a sizable fraction of COVID-19 survivors still have lasting symptoms that impair several body systems. Long-COVID patients require an urgent understanding of pathophysiological processes and the development of tailored treatments.
Keywords: a systematic review; long term covid-19; meta-analysis; prevalence; symptoms.